Enlarged mediastinal lymph nodes: causes and diagnosis

Enlarged mediastinal lymph nodes are a clinical and imaging finding, not a standalone diagnosis. Their causes range from reactive changes in common infections to granulomatous diseases and malignancies. Management always begins with an assessment of the clinical context, size, and morphology of the nodes on computed tomography, followed by morphological confirmation using minimally invasive methods if necessary. [1]

A key principle of modern practice: not all enlarged nodules require invasive verification. For asymptomatic patients with small nodules and benign features on CT, a watchful waiting approach with monitoring is acceptable. However, if a malignancy is suspected, endobronchial ultrasound transtracheal aspiration is the first-line method for morphological confirmation. [2]

Epidemiology

The increasing number of chest imaging studies has led to an increase in the incidence of incidental mediastinal lymphadenopathy. According to the American College of Radiology guidelines for incidental findings, mediastinal nodes are often discovered unrelated to the patient's primary complaint, and a significant proportion of them are benign. This has necessitated algorithms for stratification by size and imaging features. [3]

In oncology, evaluation of mediastinal nodes is critical for lung cancer staging. Current practices emphasize the role of systematic node assessment during initial staging, as node status directly influences treatment decisions and prognosis. [4]

Reasons

The causes of enlarged mediastinal lymph nodes are conventionally grouped into four major categories: reactive inflammatory, infectious, granulomatous, and neoplastic. Infectious causes include bacterial and viral agents, mycobacteria, and fungal pathogens. Granulomatous causes include sarcoidosis and tuberculosis. Neoplastic causes include lymphomas and metastatic lesions from solid tumors. [5]

Benign reactive nodules are often encountered in chronic lung diseases and after acute inflammation. They are characterized by small size and the absence of suspicious features on computed tomography. In contrast, necrosis within the nodule, conglomerates, and pronounced hypermetabolic activity on positron emission tomography (PET) increase the likelihood of a specific process and prompt verification. [6]

Risk factors

Factors that increase the likelihood of malignancy include older age, smoking, a known solid tumor, systemic symptoms such as weight loss and night sweats, and large size and abnormal morphology of the nodules on CT scan. In endemic regions, mycobacterial and fungal infections remain significant alternatives. [7]

Patients with immunodeficiencies are at higher risk for opportunistic infections, and workers with occupational exposures are more likely to experience granulomatous reactions. Context helps narrow the range of causes and determine the sequence of investigations. [8]

Pathogenesis

Node enlargement reflects lymphoid tissue proliferation and the accumulation of inflammatory cells, granulomas, or tumor cells. Caseous necrosis may develop in tuberculosis, noncaseating granulomas in sarcoidosis, and replacement of the node by tumor tissue in metastasis. These differences determine the visual characteristics and behavior on biopsy. [9]

Modern imaging complements morphological understanding: diffusion-weighted magnetic resonance imaging and diffusion coefficient calculation help to distinguish between inflammatory and neoplastic processes, although the final diagnosis still relies on morphology. [10]

Symptoms

Many patients are asymptomatic, and the nodules are discovered incidentally. Symptoms, if they occur, are related either to the underlying disease or to pressure from the massive masses on adjacent structures—cough, shortness of breath, dysphagia, and chest pain. Systemic signs such as fever, weight loss, and night sweats raise suspicion of a specific process. [11]

In infectious causes, signs of inflammation often predominate; in sarcoidosis, there is a gradual increase in weakness and respiratory symptoms; in lymphoma, there are pronounced systemic manifestations. The clinical picture guides the choice of initial tests. [12]

Forms and stages

Topographically, the anterior, middle, and posterior mediastinum are distinguished, which helps narrow the differential diagnosis: for example, lymphomas and thymus-associated lesions are typical for the anterior segment, tracheobronchial chain nodes for the middle segment, and neurogenic lesions with possible nodal involvement for the posterior segment. The distribution of nodes by segment is also important in staging lung cancer. [13]

Based on their dynamics, a distinction is made between transient reactive lymphadenopathy and persistent enlargement. Transient nodes tend to regress during follow-up, while persistent nodes require in-depth evaluation with morphological verification if suspicious signs are present. [14]

Complications and consequences

The main risks are associated with missing a significant diagnosis or with overly aggressive treatment of benign nodules. Delayed verification of a tumor can change the stage and deprive the patient of optimal treatment. Conversely, unnecessary invasive interventions increase the risk of bleeding and infection. A balance is achieved by strictly following algorithms. [15]

In cases of severe lymphadenopathy, mechanical complications are possible: compression of the airways, superior vena cava, and esophagus. These situations require rapid diagnosis and decompression while initiating etiotropic therapy. [16]

Diagnostics

The basic step is a high-quality computed tomography scan of the chest organs, assessing short-axis dimensions, shape, contour clarity, the presence of necrosis, fatty inclusions, calcifications, and the context within the lung parenchyma. In cases of benign signs and small sizes, follow-up is possible without immediate biopsy. [17]

If a malignancy is suspected or if the nodules are clinically significant, morphological verification is indicated. The method of choice is endobronchial ultrasound-guided transtracheal aspiration, which became the first invasive procedure due to its high diagnostic accuracy and safety. The choice of needle gauge and collection technique are standardized by international guidelines. [18]

Positron emission tomography improves the sensitivity of lung cancer staging, but does not replace biopsy due to false-positive results in inflammation and granulomatosis. Magnetic resonance imaging techniques are being developed as a complementary technique, but also do not eliminate the need for morphological confirmation in ambiguous cases. [19]

Table 1. When to observe and when to biopsy

Clinical scenario	Short axis size and features	Recommended action
Asymptomatic patient, benign signs	Less than 15 mm, clear contours, no necrosis	Control computed tomography after 3-6 months according to algorithms of incidental findings
Tumor risk factors or worrisome morphology	15 mm or more, conglomerates, necrosis, unclear contours	Morphological verification, preferably endobronchial ultrasound aspiration
Known solid tumor staging	Any suspicious node	Routine verification of staging schemes before treatment
[20]

Differential diagnosis

Benign reactive nodules should be distinguished from granulomatous diseases: sarcoidosis typically exhibits symmetrical bilateral enlargement of the hilar and mediastinal nodes, while tuberculosis more often reveals necrosis and calcifications. These features guide the selection of tests, including immunological tests and microbiology. [21]

Metastatic lesions and lymphomas are differentiated by clinical context, site distribution, and morphology. In the presence of a history of cancer, the action plan is determined by staging standards, with a priority given to minimally invasive biopsy. If lymphoma is suspected, a core biopsy is important to preserve the nodal architecture. [22]

Table 2. Image clues and probable causes

Signs on CT scan	More likely reasons	Next steps
Symmetrical bilateral enlargement of the roots and mediastinum	Sarcoidosis	Serological markers, target organ assessment, biopsy if necessary
Nodes with central necrosis	Tuberculosis, metastases of squamous cell carcinoma	Microbiology and morphology, epidemiological context
Large conglomerates without calcifications	Lymphoma	Morphology, preferably core biopsy
Single nodes against the background of a lung tumor	Metastatic lesion	Endobronchial ultrasound aspiration for staging
[23]

Treatment

Treatment tactics are determined by the underlying cause. Reactive benign nodules do not require specific therapy and are observed. Infectious causes require etiotropic treatment based on the pathogen. Granulomatous diseases are managed according to specialized recommendations using anti-inflammatory or antimicrobial regimens. Tumor lesions are treated within the framework of oncology protocols after accurate staging. [24]

In lung cancer, minimally invasive morphological verification of nodules using endobronchial ultrasound aspiration is the first-line standard. This allows for accurate staging of the disease and selection of the optimal treatment method—surgery, systemic therapy, radiation therapy, or a combination thereof. Specialized centers have standardized the puncture technique and the volume of material for immunohistochemistry and molecular testing. [25]

In sarcoidosis, treatment decisions depend on target organs and symptom severity; a stepwise strategy with steroids as an initial therapy and steroid-sparing agents as needed is often used. In tuberculosis, a standard multi-tiered antimycobacterial regimen is used, taking into account resistance. Correct initial routing reduces the time to effective therapy. [26]

Table 3. Treatment logic by categories of causes

Category	The main goal	First line	Comments
Reactive nodes	Avoid overdiagnosis	Observation and control images	Follow size thresholds and signs of benignity
Infections	Eradication of the pathogen	Etiotropic antimicrobial therapy	Adjust according to microbiology and epidemiological context
Granulomatosis	Inflammation control	Anti-inflammatory therapy according to the disease profile	Target organ and risk assessment
Tumors	Correct staging and disease control	Endobronchial ultrasound aspiration, hereinafter referred to as the oncoprotocol	Sufficient material for molecular testing is required
[27]

Prevention

Non-specific prevention involves controlling risk factors for lung diseases and infections: smoking cessation, vaccination against pneumococcus and influenza in risk groups, early treatment of respiratory tract infections, and adherence to measures to prevent aspiration in vulnerable patients. These measures reduce the likelihood of reactive lymphadenopathy and complications. [28]

In oncology, prevention comes down to early detection and correct staging: for suspicious nodules in high-risk patients, it is important to promptly refer them for morphological verification to centers with standardized minimally invasive techniques. This directly improves outcomes. [29]

Forecast

The prognosis depends on the cause. For benign reactive nodules, the prognosis is favorable; for granulomatosis, it varies and improves with early initiation of appropriate therapy. In tumor lesions, the prognosis is determined by the stage and biology of the tumor, and timely morphological verification of the nodules improves the accuracy of staging and treatment selection. [30]

For incidentally discovered small nodules with benign features, the risk of clinically significant progression is low, allowing for safe avoidance of invasive interventions and limited observation based on incidental findings. This reduces the burden on the patient and the healthcare system. [31]

Frequently asked questions

• Is a biopsy of enlarged mediastinal nodes always necessary?

No. If the tumor is asymptomatic, less than fifteen millimeters in size, and has benign morphology, observation with repeat CT scanning is acceptable. A biopsy is necessary in the presence of suspicious signs, risk factors, and in an oncological context. [32]

• Which method of morphological verification is currently considered the first?

In most cases, endobronchial ultrasound aspiration is used as a minimally invasive, accurate, and safe procedure. Needle selection and technique are regulated by current guidelines. [33]

• How useful is positron emission tomography?

It is very useful for staging and identifying metabolically active nodules, but does not replace biopsy due to false-positive results in inflammatory and granulomatous diseases. The decision is always made by a multidisciplinary team. [34]